AMH-targeted Therapies (via Oviva Therapeutics)

About Granata Bio

Granata Bio is a private, clinical-stage biopharma company targeting the underserved US fertility therapeutics market. The company employs a capital-efficient 'search and develop' model, in-licensing established IVF medications from outside the US and advancing them through clinical development and regulatory approval for the North American market. With a pivotal Phase III trial underway for a key gonadotropin asset and the 2025 acquisition of Oviva Therapeutics, Granata Bio is positioning itself as a new competitor aimed at increasing treatment options, spurring innovation, and potentially lowering costs for patients. The company is led by a team with deep reproductive health expertise and is supported by a network of stakeholders in the fertility field.

Therapeutic Areas